Pembrolizumab‐Induced Steroid‐Responsive Myoclonus

Gallagher, Amy; Murphy, Michael; McDermott, Ray; Alexander, Michael; O’Dowd, Seán

doi:10.1002/mdc3.13453

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of 5682 eligible papers, 26 articles 8–33 reporting 28 patients were included. A detailed PRISMA flowchart, the assessment of the risk of bias for each study, and the estimation of frequency in larger cohorts of patients with neurological irAEs are provided in Supporting Information.…”

Section: Resultsmentioning

confidence: 99%

Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors

Dinoto,

Trentinaglia,

Carta

et al. 2024

Movement Disord Clin Pract

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICI) may trigger autoimmune neurological conditions, including movement disorders (MD).ObjectivesThe aim of this study was to characterize MDs occurring as immune‐related adverse events (irAEs) of ICIs.MethodsA systematic literature review of case reports/series of MDs as irAEs of ICIs was performed.ResultsOf 5682 eligible papers, 26 articles with 28 patients were included. MDs occur as a rare complication of cancer immunotherapy with heterogeneous clinical presentations and in most cases in association with other irAEs. Inflammatory basal ganglia T2/fluid attenuated inversion recovery abnormalities are rarely observed, but brain imaging is frequently unrevealing. Cerebrospinal fluid findings are frequently suggestive of inflammation. Half of cases are associated with a wide range of autoantibodies. Steroids and ICI withdrawal usually lead to improvement, even though some patients experienced relapses or a severe clinical course.ConclusionMDs are a rare complication of ICIs that should be promptly recognized to offer patients a correct diagnosis and treatment.

show abstract

Section: Resultsmentioning

confidence: 99%